Table 1.
Characteristics of included articles.
| First author | Year | Country | Sample size | Diagnostic criteria | Mean age | RA patients (%) | |||
|---|---|---|---|---|---|---|---|---|---|
| Total | M/F | Total | Male | Female | |||||
| Turgunova et al. (17) | 2021 | Kazakhstan | 101 | 31/70 | IDF | - | 40.5 | - | - |
| Hee et al. (18) | 2021 | Singapore | 561 | 0/561 | NCEP/ATP III | - | 44.9 | - | - |
| JC 2009 | - | 49.4 | - | - | |||||
| Giraud et al. (19) | 2021 | France | 75 | 20/55 | WHO | 59.2 | 28 | - | - |
| Kong et al. (20) | 2021 | China | 717 | 152/565 | CDS | 61 | 31.2 | - | - |
| Cioffi et al. (21) | 2021 | Italy | 228 | - | IDF | 58 | 15 | - | - |
| Mobini et al. (13) | 2020 | Iran | 200 | - | NCEP/ATP III | - | 54.5 | - | - |
| IDF | 56 | - | - | ||||||
| Garcia-Chagollan et al. (4) | 2020 | Mexico | 216 | 22/194 | NCEP/ATP III | 46 | 30.6 | - | - |
| ALAD | 28.7 | - | - | ||||||
| Xu et al. (22) | 2020 | Korea | 247 | 48/199 | NCEP/ATP III | 58 | 15 | - | - |
| Shaikh et al. (23) | 2020 | Pakistan | 104 | 10/94 | NCEP/ATP III | 33.4 | 32.7 | - | - |
| Ozkul et al. (24) | 2019 | Turkey | 50 | 11/39 | IDF | 56.9 | 36 | - | - |
| Mulumba et al. (3) | 2019 | Congo | 75 | 15/60 | NCEP/ATP III | 51.8 | 25.3 | - | - |
| Ene et al. (25) | 2019 | Romania | 120 | 31/89 | IDF-NCEP/ATP III | 52.7 | 39.2 | 45.2 | 37.1 |
| Naidu et al. (26) | 2019 | India | 114 | 21/93 | NCEP/ATP III | 44.8 | 31.6 | - | - |
| Kuriya et al. (27) | 2019 | USA | 1543 | 443/1100 | WHO | 54 | 30.8 | 42 | 26 |
| Akbal et al. (28) | 2019 | Turkey | 53 | 12/41 | ATP III | 51 | 47.1 | - | - |
| Aleksic et al. (29) | 2019 | Serbia | 81 | 19/62 | IDF | 59.7 | 54.3 | - | - |
| Mobini et al. (30) | 2018 | Iran | 140 | 25/115 | NCEP/ATP III | 44.7 | 31.4 | - | - |
| IDF | 35 | - | - | ||||||
| Gomes et al. (7) | 2018 | Brazil | 338 | 31/307 | NCEP/ATP III | 53.5 | 51.3 | - | - |
| Burggraaf et al. (31) | 2017 | Netherland | 212 | 65/147 | NCEP/ATP III | 54 | 40.1 | - | - |
| Slimani et al. (32) | 2017 | Algeria | 249 | 36/213 | NCEP/ATP III | 50.1 | 13.9 | 14.3 | 13.8 |
| Pandey et al. (33) | 2017 | India | 84 | 18/66 | ATP III 2004 | 44.8 | 39.2 | - | - |
| Ostojic et al. (34) | 2016 | Serbia | 36 | 6/30 | - | 36 | 30.6 | - | - |
| Lee et al. (35) | 2016 | Korea | 598 | 110/488 | AHA/NHLBI | 63.6 | 36.4 | 34.5 | 36.9 |
| Hugo et al. (36) | 2016 | France | 57 | 15/42 | IDF | 57.6 | 24 | 25 | 24 |
| Zafar et al. (37) | 2016 | Pakistan | 384 | 97/277 | NCEP/ATP III | 43.8 | 31.3 | 18.5 | 35.5 |
| Oliveira et al. (38) | 2016 | Brazil | 107 | 0/107 | NCEP/ATP III | 55.5 | 51.4 | - | 51.4 |
| IDF | 53.4 | - | 53.4 | ||||||
| Muller et al. (39) | 2016 | Estonia | 91 | 66/25 | NCEP/ATP III | 51.6 | 35 | - | - |
| Dihingia et al. (40) | 2016 | India | 72 | 6/66 | NCEP/ATP III | 41.5 | 16.7 | - | - |
| Ghazaly et al. (41) | 2015 | Egypt | 80 | 13/67 | ATP III | 40.7 | 50 | 53 | 49.2 |
| Salamon et al. (42) | 2015 | Croatia | 583 | 100/483 | ATP III | 59 | 43.1 | 40 | 43.7 |
| Tantayakom et al. (43) | 2015 | Thailand | 267 | 31/236 | NCEP/ATP III | 59 | 16.1 | 12.9 | 16.5 |
| Parra-Salcedo et al. (44) | 2015 | Mexico | 160 | 18/142 | AHA/NHLBI | 38.1 | 28 | - | - |
| IDF | 18 | - | - | ||||||
| NCEP/ATP III | 24 | - | - | ||||||
| Craciun et al. (12) | 2014 | Romania | 51 | 7/44 | IDF-AHA | 55.2 | 19 | 10.5 | 82.4 |
| NCEP/ATP III | 23 | - | - | ||||||
| IDF | 18 | - | - | ||||||
| AHA | 14 | - | - | ||||||
| Bilecik et al. (45) | 2014 | Turkey | 100 | 0/100 | IDF | 52 | 33 | - | 33 |
| NCEP/ATP III | 27 | - | 27 | ||||||
| Ozmen et al. (46) | 2014 | Turkey | 52 | 15/37 | NCEP/ATP III | 51 | 17.3 | - | - |
| WHO | 28.8 | - | - | ||||||
| Kumar et al. (47) | 2014 | India | 54 | 6/48 | IDF | 46 | 29 | - | - |
| NCEP/ATP III | 31 | - | - | ||||||
| Abourazzak et al. (48) | 2014 | Morocco | 179 | 22/157 | IDF | 49 | 30.7 | - | - |
| NCEP/ATP III | 29 | - | - | ||||||
| AACE 2003 | 24 | - | - | ||||||
| Salinas et al. (49) | 2013 | Argentina | 409 | 69/340 | ATP III | 55.5 | 30 | 62 | 23.8 |
| IDF | 35 | - | - | ||||||
| Abdul-Qaharr et al. (50) | 2013 | Iraq | 203 | 41/162 | NCEP/ATP III | 46.9 | 51.2 | 12 | 92 |
| Rostom et al. (51) | 2013 | Morocco | 120 | 10/110 | NCEP/ATP III 2004 | 49 | 30.8 | 10 | 32.7 |
| NCEP/ATP III 2001 | 24.6 | - | - | ||||||
| WHO | 20 | - | - | ||||||
| IDF | 48.6 | - | - | ||||||
| EGIR | 18 | - | - | ||||||
| JC 2009 | 32.3 | - | - | ||||||
| Lee et al. (52) | 2013 | Korea | 84 | 0/84 | NCEP/ATP III | 50.6 | 19 | - | 19 |
| Ormseth et al. (53) | 2013 | USA | 162 | 18/144 | ATP III | 54 | 26 | - | - |
| Karakoc et al. (1) | 2012 | Turkey | 54 | 7/47 | IDF | 49.8 | 42.6 | - | - |
| Manka et al. (54) | 2012 | Slovakia | 87 | 4/83 | IDF | 58.8 | 48.3 | - | - |
| NCEP/ATP III | 44.8 | - | - | ||||||
| AHA/NHLBI | 47.1 | - | - | ||||||
| Da Cunha et al. (55) | 2012 | Brazil | 283 | 50/233 | NCEP/ATP III | 56.8 | 39.2 | - | - |
| Goshayeshi et al. (56) | 2012 | Iran | 120 | 14/106 | NCEP/ATP III | 45.5 | 45.2 | - | - |
| Baker et al. (57) | 2012 | USA | 499 | 83/416 | IDF | 49.5 | 10.6 | - | - |
| Crowson et al. (58) | 2011 | USA | 232 | 58/174 | NCEP/ATP III | 58.8 | 33 | 36 | 32 |
| Sahebari et al. (59) | 2011 | Iran | 120 | 14/106 | IDF | 45.5 | 30.8 | 28.6 | 41.5 |
| NCEP/ATP III | 45.2 | 28.6 | 37.7 | ||||||
| Karimi et al. (60) | 2011 | Iran | 92 | 0/92 | NCEP | 48.3 | 27.2 | - | 27.2 |
| WHO | 19.6 | - | 19.6 | ||||||
| Mok et al. (61) | 2011 | Hong Kong | 699 | 133/566 | JS 2009 | 53.3 | 20 | - | - |
| Dao et al. (62) | 2010 | Vietnam | 105 | 0/105 | IDF | 56.3 | 40.9 | - | - |
| NCEP/ATP III 2004 | 32.4 | - | - | ||||||
| NCEP/ATP III 2001 | 24.7 | - | - | ||||||
| JS 2009 | 32.4 | - | - | ||||||
| WHO | 19 | - | - | ||||||
| EGIR | 16.2 | - | - | ||||||
| Raterman et al. (63) | 2010 | Netherland | 236 | 79/157 | NCEP | 62.1 | 19.9 | - | - |
| Solomon et al. (64) | 2010 | South Africa | 291 | 32/259 | NCEP/ATP III | 27.2 | 31.3 | - | - |
| 335 | 65/270 | NCEP/ATP III | 27.2 | 20.3 | - | - | |||
| Giles et al. (65) | 2010 | USA | 131 | 51/80 | NCEP/ATP III | 61 | 36 | - | - |
| Santos et al. (66) | 2010 | Portugal | 98 | 0/98 | ATP III | 49.2 | 25.5 | - | - |
| Toms et al. (67) | 2009 | UK | 387 | 105/282 | IDF | 63.1 | 45.3 | 52.7 | 42.6 |
| NCEP/ATP III 2004 | 40.1 | 42.5 | 39.2 | ||||||
| NCEP/ATP III 2001 | 38.3 | 40 | 37.7 | ||||||
| WHO | 19.4 | 25.5 | 17.2 | ||||||
| EGIR | 12.1 | 22.6 | 8.2 | ||||||
| Chung et al. (2) | 2008 | USA | 66 | 18/48 | WHO | 59 | 42 | - | - |
| Zonana-Nacach et al. (68) | 2008 | Mexico | 107 | - | NCEP/ATP III | 42.9 | 18.7 | - | - |
| Karvounaris et al. (69) | 2007 | Greece | 200 | 53/147 | ATP III | 63 | 44 | 39.6 | 45.6 |
| Montagna et al. (70) | 2007 | Italy | 45 | 3/42 | NCEP/ATP III | 53.8 | 55.5 | - | - |